Enara Bio Ltd.

Enara Bio Ltd. is a biopharmaceutical company focused on developing innovative cancer immunotherapies targeting a unique class of cancer-specific targets known as Dark Antigens. Founded in 2016 in Oxford, UK, Enara Bio Ltd. specializes in cancer immunotherapy.

The company successfully raised GBP 24. 7 mn in its Series B funding round on September 3, 2024, with investments from Pfizer Venture Investments, M Ventures, and others. Enara Bio has completed a total of five funding rounds and operates as an independent entity without any known subsidiaries or parent companies. Enara Bio specializes in the development of cancer immunotherapies that target a novel class of cancer-specific targets known as Dark Antigens.

Their primary technology platform, EDAPT®, integrates multifaceted approaches including bioinformatics, immunopeptidomics, target validation, and immunology to identify and leverage previously uncharted genomic dark matter. This innovative methodology enables the discovery of unique antigens that can elicit immune responses against cancer cells, particularly focusing on non-small cell lung cancer (NSCLC). In 2023, Enara Bio reported a revenue of GBP 21. 66 mn and an EBITDA of GBP 3.

49 mn. Their revenue model is centered around strategic partnerships and collaboration agreements with leading pharmaceutical companies, generating income through licensing agreements, milestone payments, and royalties tied to the development of immunotherapy products. Enara Bio plans to utilize the GBP 24. 7 mn raised in Series B funding to advance its pipeline of TCR-based immunotherapies targeting novel Dark Antigens for solid tumors.

The company is expected to focus on expanding its market reach and enhancing its therapeutic offerings. Specific new products are under development, although further details on release dates and targeted market expansions are yet to be disclosed.